_256_384.jpg)
News | June 19, 2024
Cipla EU to invest an additional € 3 million in Ethris
Cipla had earlier invested € 15 million in Ethris in 2022
Cipla had earlier invested € 15 million in Ethris in 2022
The new facility will accelerate the biotech and pharmaceutical industry's development by manufacturing vaccines, cell and gene therapies, and protein-based therapies
Bluecrux's digital supply chain twin technology, Axon, plays a critical role in Sanofi's digital supply chain transformation.
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Sales reflect continued strong growth in oncology and vaccines
The demand in Africa for COVID-19 vaccines has declined
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Subscribe To Our Newsletter & Stay Updated
